InflaRx N.V. (NASDAQ: IFRX)

InflaRx N.V., a clinical-stage biopharmaceutical company, is focused on developing first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and small molecule inhibitors of C5aR. The company's lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

InflaRx is developing vilobelimab for the treatment of several inflammatory diseases, including pyoderma gangraenosum (PG), severe COVID-19, cutaneous squamous cell carcinoma (cSCC), hidradenitis suppurativa (HS), and ANCA-associated vasculitis (AAV). The company is also developing IFX002, a life-cycle management product for vilobelimab, and INF904, an orally administered, small-molecule inhibitor of C5aR.

The company's technology is based on the understanding that C5a is a key inflammatory mediator driving tissue damage in many inflammatory diseases. C5a is a small, 74-amino acid-spanning protein that creates an inflammatory environment by attracting and strongly activating neutrophils, as well as causing many different cell types to generate pro-inflammatory and inflammation-related molecules. C5a has been shown to play a key role in neutrophil-driven inflammatory diseases, including hidradenitis suppurativa, and blocking it may have a positive effect on T-cell function, overall control of the inflammatory status of the disease, and a strong anti-inflammatory effect on neutrophils (InflaRx N.V., 2